MedTrace Logo

Efficacy of Belatacept in Reducing DSA

NCT02078193 · Status: COMPLETED · Phase: PHASE4 · Type: INTERVENTIONAL · Enrollment: 3

Last updated 2017-08-01

Study results available
· View outcomes & findings →

Summary

The primary objective of this study is to demonstrate that administration of belatacept in maintenance kidney transplant recipients may cause a reduction in Donor Specific HLA Antibody (DSA).

Conditions

  • Kidney Transplantation

Interventions

DRUG

Belatacept

Patients will be converted from their MMF to Belatacept

Sponsors & Collaborators

  • East Carolina University

    lead OTHER

Principal Investigators

  • Paul Bolin, MD · East Carolina University, Department Chair of Internal Medicine

Study Design

Allocation
NA
Purpose
TREATMENT
Masking
NONE
Model
SINGLE_GROUP

Eligibility

Min Age
18 Years
Max Age
75 Years
Sex
ALL
Healthy Volunteers
Yes

Timeline & Regulatory

Start
2013-11-30
Primary Completion
2016-07-31
Completion
2016-07-31

Countries

  • United States

Study Locations

More Related Trials

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT02078193 on ClinicalTrials.gov